East China Pharmaceutical Subsidiary Receives FDA Approval for Clinical Trial
East China Pharmaceutical announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical trial in the United States. According to Jin10, the trial will focus on the injectable drug HDM2024, which is intended for the treatment of advanced solid tumors. This approval marks a significant step for the company in expanding its research and development efforts internationally.
Source: CoinLive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments